SGS Life Science Services, a division of the SGS Group, has expanded its Phase I units in Antwerp Stuivenberg hospital (Belgium) by adding 22 new hospitalization beds. The clinical pharmacology unit brings the total number of beds to 102 for Belgium, and brings SGS's global capacity to 184 beds.
More information is available in the official Media Information document (PDF 28 KB):
SGS' Life Science Services has 30 years of experience as a global contract service organization providing integrated solutions from preclinical activities to Phase I-IV trials, Bioanalytical and QC testing. With innovative study designs, optimal facilities and strong regulatory intelligence, SGS can favourably impact client's drug development timelines and decision-making.
For more information, please visit our website, www.sgs.com/CRO"
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.